ACXP logo

ACURX PHARMACEUTICALS INC

ACXPNASDAQ
🏆 #5153 by market capEarnings Nov 10US Equity
$1.30▼ $0.06 (−4.76%)
Live
🔔
Track ACXP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.8%
7d▼ 5.8%
14d▼ 4.1%
30d▼ 10.0%
ytd▼ 52.7%
1y▼ 68.1%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$1.28 – $1.33
52-Week Range
$1.31 – $8.34
Volume
$2.42B
Avg Volume
$1.90B
Shares Outstanding
4.3M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$450,570
Last Q Revenue
$112,504
P/E Ratio
-0.4
P/S Ratio
0.0x
EPS (TTM)
$-1.76
Dividend Yield
0.00%
Dilution (1yr)
+76.0%

Why Investors Own ACXP

  • ✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 77% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACXP logo

ACURX PHARMACEUTICALS INC

ACXP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −42.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −34.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.5M▲ +76.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$4M YoY
StockOtter · stockotter.space

About ACURX PHARMACEUTICALS INC

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

ACURX PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift ACXP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ACURX PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.